PHS 2023-2 Omnibus Solicitations of the NIH, CDC, and FDA for SBIR and STTR have been released
The PHS 2023-2 omnibus solicitations of the NIH, CDC, and FDA for Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grant applications have been released. The first application due date is Tuesday, September 5, 2023, so start preparing your application today. As usual, there are four Omnibus Solicitations:
- PA-23-230: PHS 2023-2 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
- PA-23-231: PHS 2023-2 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required)
- PA-23-232: PHS 2023-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)
- PA-23-233: PHS 2023-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required)
Please note: The SBIR and STTR Extension Act of 2022 (the Act), signed into law by President Biden on September 30, 2022, reauthorized the SBIR program, the STTR program, and related pilot programs through September 30, 2025.
The Act includes major changes to the SBIR and STTR programs, including:
- Increased minimum performance standards (refer to NOT-OD-23-092),
- Pre- and Post- award foreign disclosure requirements (refer to NOT-OD-23-139, view the required form).
Additionally, peer review criteria have changed. As these are significant changes, applicants are urged to read the solicitations in full.
Questions? Contact SEEDinfo@nih.gov.
